Issues related to gene therapy. Issues related to plasma therapies. H.R. 2666, the Medicaid VBPs for Patients (MVP) Act and issues related to value-based payment arrangements. Monitored implementation of P.L. 117-169, the Inflation Reduction Act, as it relates to plasma derived products and drug pricing. Monitored issues related to pharmacy benefit management. Issues related to drug shortages. Issues related to the Medicaid Drug Rebate Program. H.R.6465, PLASMA Act - Preserving Life-saving Access to Specialty Medicines in America Act.
Monitored issues related to medical supply chain and pharmacy benefit management. Monitored issues related to drug pricing.
H.R.7024, Tax Relief for American Families and Workers Act of 2024, as it relates to the R&D tax credit. Monitored H.R. 3665, Defending American Jobs & Investment Act, as it relates to taxation of foreign-based multinationals.
Duration: January 15, 2019
to
present
General Issues: Medicare/Medicaid , Health Issues , Taxation/Internal Revenue Code , Homeland Security , Government Issues , Budget/Appropriations , Banking
Spending: about $1,050,000 (But it's complicated. Here's why.)
It can be tricky to figure out how much an organization spent on a particular lobbying engagement. The law only requires lobbyists to report the amount they were paid for federal lobbying each quarter rounded to the nearest $10,000—and if it's less than $3,000 in a given quarter (or less than $13,000 for organizations with in-house lobbyists), they don't have to disclose it at all. Plus, some organizations include spending that doesn’t belong in the report—for instance, money spent lobbying state governments or other legal work.
Agencies lobbied since 2019: U.S. Senate, House of Representatives, White House Office, Health & Human Services - Dept of (HHS), Centers For Medicare and Medicaid Services (CMS), Executive Office of the President (EOP), Homeland Security - Dept of (DHS)
Related Foreign Entities:
CSL Limited (Parkville, Victoria , AUS); contribution to lobbying: $0; ownership 100%
Lobbyists
Lobbyists named here were listed on a filing related to this lobbying engagement. They may not be working on it now. Occasionally, a single lobbyist whose name is spelled two different ways on filings may be represented twice here.
Lobbyist
Covered positions?
Mary Beth Savary Taylor Joint Economic Committee, General Counsel;
U.S. Senator Connie Mack, Legislative Assistant
Stacey Hughes U.S. Senate Budget Cmte, Dpty Staff Dir;Ofce of the Asst. Maj. Ldr (Sen. Nickles), Policy Adv; Office of the Asst. Min. Ldr (Sen. Nickles), Policy Adv.;Senate Spec. Cmte on Aging (Sen.Cohen),Prof. Staff Member; U.S.Sen Connie Mack, Leg Asst/Schdlr
Emily Porter Ofce of Spkr(Rep.Boehner),Asst to Spkr,Policy;Ofce of
Min.Ldr.(Rep.Boehner),Plcy Adv;Ofce of the Maj. Ldr(Rep. Boehner),Plcy Adv;Cmte Ed & the Wrkfrc(Rep.Boehner),Coalitions Dir. for Educ Plcy; Rep.Trent Franks,Sr.Leg.Asst; Rep.Tom Tancredo,Leg.Asst
Rachel Jones Hensler U.S. Senate Budget Committee, Tax Policy Dir.; Office of U.S. Senator Fred Thompson, Legislative Assistant; Office of U.S. Senator Dave Durenberger, Legislative Assistant; Office of U.S. Senator Dave Durenberger, Legislative Correspondent
Don Kent U.S. Sen Ron Johnson, Chief of Staff; DHS Secretary Michael Chertoff, Asst Sec; DHS Secretary Tom Ridge, Deputy Asst Sec; U.S. Senate Budget Committee, Policy Adv; Office of the Asst. Maj. Leader Nickles Policy Adv.;U.S. Senator Don Nickles,Leg Asst
Greg D'Angelo White House Office of Management and Budget, Associate Director of Health Programs;
Senate Committee on the Budget (Sen. Gregg, Sen. Sessions, and Sen. Enzi), Professional Staff Member.
Brett Baker U.S. Senate Committee on Finance (Senators Crapo, Grassley, and Hatch)-Deputy Health Policy Director; Health Policy Dir.; Senior Policy Advsr; Policy Advisor. U.S. House of Representatives Committee on Ways and Means (Reps. Camp and Ryan) Prof. Staff
Stephanie Badger n/a
Disclosures Filed
Once a lobbying engagement begins, the lobbyist or firm is required to file updates four times a year. Those updates sometimes change which lobbyists are involved or add new issues being discussed. When lobbyists stop working for a client, the firm is also supposed to file a report disclosing the end of the relationship.
1st Quarter, 2024
In Q1, THE NICKLES GROUP, LLC lobbied for CSL Behring LLC , earning $50,000. The report was filed on April 22.
Original Filing: 301573715.xml
Lobbying Issues
Issues related to gene therapy. Issues related to plasma therapies. H.R. 2666, the Medicaid VBPs for Patients (MVP) Act and issues related to value-based payment arrangements. Monitored implementation of P.L. 117-169, the Inflation Reduction Act, as it relates to plasma derived products and drug pricing. Monitored issues related to pharmacy benefit management. Issues related to drug shortages. Issues related to the Medicaid Drug Rebate Program. H.R.6465, PLASMA Act - Preserving Life-saving Access to Specialty Medicines in America Act.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Monitored issues related to medical supply chain and pharmacy benefit management. Monitored issues related to drug pricing.
Agencies Lobbied
U.S. Senate
Lobbying Issues
H.R.7024, Tax Relief for American Families and Workers Act of 2024, as it relates to the R&D tax credit. Monitored H.R. 3665, Defending American Jobs & Investment Act, as it relates to taxation of foreign-based multinationals.
Agencies Lobbied
U.S. Senate
Type of Issue
Taxation/Internal Revenue Code
4th Quarter, 2023
In Q4, THE NICKLES GROUP, LLC lobbied for CSL Behring LLC , earning $50,000. The report was filed on Jan. 19.
Original Filing: 301530074.xml
Lobbying Issues
Issues related to gene therapy. Issues related to plasma therapies. H.R. 2666, the Medicaid VBPs for Patients (MVP) Act and issues related to value-based payment arrangements. Issues related to drug shortages. Monitored implementation of P.L. 117-169, the Inflation Reduction Act, as it relates to plasma derived products and drug pricing. Monitored issues related to pharmacy benefit management. Issues related to the Medicaid Drug Rebate Program.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Monitored issues related to medical supply chain and pharmacy benefit management. Monitored issues related to drug pricing.
Agencies Lobbied
U.S. Senate
Lobbying Issues
S. 866, the American Innovation and Jobs Act, and H.R. 3938, Build It in America Act, and issues related to the R&D tax credit. Monitored H.R. 3665, Defending American Jobs & Investment Act, as it relates to taxation of foreign-based multinationals.
Agencies Lobbied
U.S. Senate
Type of Issue
Taxation/Internal Revenue Code
Lobbying Issues
Monitored issues related to plasma donation.
3rd Quarter, 2023
In Q3, THE NICKLES GROUP, LLC lobbied for CSL Behring LLC , earning $50,000. The report was filed on Oct. 18, 2023.
Original Filing: 301505353.xml
Lobbying Issues
Issues related to gene therapy. Issues related to plasma therapies. H.R. 2666, the Medicaid VBPs for Patients (MVP) Act and issues related to value-based payment arrangements. Monitored implementation of P.L. 117-169, the Inflation Reduction Act, as it relates to plasma derived products and drug pricing. Issues related to drug pricing. Monitored issues related to pharmacy benefit management. Issues related to the Medicaid Drug Rebate Program.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Monitored issues related to medical supply chain and pharmacy benefit management.
Agencies Lobbied
U.S. Senate
Lobbying Issues
S. 866, the American Innovation and Jobs Act, and H.R. 3938, Build It in America Act, and issues related to the R&D tax credit. Monitored H.R. 3665, Defending American Jobs & Investment Act, as it relates to taxation of foreign-based multinationals.
Agencies Lobbied
U.S. Senate
Type of Issue
Taxation/Internal Revenue Code
Lobbying Issues
Monitored issues related to plasma donation.
2nd Quarter, 2023
In Q2, THE NICKLES GROUP, LLC lobbied for CSL Behring LLC , earning $50,000. The report was filed on July 20, 2023.
Original Filing: 301490815.xml
Lobbying Issues
Issues related to gene therapy. Issues related to plasma therapies. H.R. 2666, the Medicaid VBPs for Patients (MVP) Act and issues related to value-based payment arrangements. Monitored implementation of P.L. 117-169, the Inflation Reduction Act, as it relates to plasma derived products and drug pricing. Monitored issues related to insulin. Monitored issues related to pharmacy benefit management.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Monitored issues related to medical supply chain and pharmacy benefit management.
Agencies Lobbied
U.S. Senate
Lobbying Issues
S. 866, the American Innovation and Jobs Act, and H.R. 3938, Build It in America Act, and issues related to the R&D tax credit. Monitored H.R. 3665, Defending American Jobs & Investment Act, as it relates to taxation of foreign-based multinationals.
Agencies Lobbied
U.S. Senate
Type of Issue
Taxation/Internal Revenue Code
Lobbying Issues
Monitored issues related to plasma donation.
1st Quarter, 2023
In Q1, THE NICKLES GROUP, LLC lobbied for CSL Behring LLC , earning $50,000. The report was filed on April 20, 2023.
Original Filing: 301465423.xml
Lobbying Issues
Issues related to gene therapy. Issues related to plasma therapies. Monitored issues related to value-based payment arrangements. Monitored implementation of P.L. 117-169, the Inflation Reduction Act, as it relates to plasma derived products and drug pricing.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Monitored issues related to medical supply chain and pharmacy benefit management.
Agencies Lobbied
U.S. Senate
Lobbying Issues
S. 866, the American Innovation and Jobs Act, and issues related to the R&D tax credit.
Agencies Lobbied
U.S. Senate
Type of Issue
Taxation/Internal Revenue Code
Lobbying Issues
Monitored issues related to plasma donation.
4th Quarter, 2022
In Q4, THE NICKLES GROUP, LLC lobbied for CSL Behring LLC , earning $50,000. The report was filed on Jan. 19, 2023.
Original Filing: 301434817.xml
Lobbying Issues
Issues related to gene therapy. Issues related to plasma therapies. Monitored issues related to value based payment arrangements. Monitored implementation of H.R. 5376 (P.L. 117-169), the Inflation Reduction Act, as it relates to plasma derived products and drug pricing.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Monitored issues related to the medical supply chain. S. 4348, FDASLA Act of 2022 and H.R. 7667, Food and Drug Amendment of 2022, including issues related to PDUFA and accelerated approval pathways. H.R. 2617 (P.L. 117-328), the Consolidated Appropriations Act of 2023, as it relates to the FDA including modernizing accelerated approval and clinical trial diversity.
Agencies Lobbied
U.S. Senate
Lobbying Issues
H.R. 2617 (P.L. 117-328), the Consolidated Appropriations Act of 2023, as it relates to amortization of R&D expenses. Monitored H.R. 1304, the American Innovation and R&D Competitiveness Act; and S. 749, the American Innovation and Jobs Act; and issues related to the R&D tax credit.
Agencies Lobbied
U.S. Senate
Type of Issue
Taxation/Internal Revenue Code
Lobbying Issues
Monitored issues related to plasma donation.
3rd Quarter, 2022
In Q3, THE NICKLES GROUP, LLC lobbied for CSL Behring LLC , earning $50,000. The report was filed on Oct. 20, 2022.
Original Filing: 301413706.xml
Lobbying Issues
Issues related plasma therapies. Monitored issues related to value based payment arrangements. H.R. 5376 (P.L. 117-169), the Inflation Reduction Act, as it relates to plasma derived products and drug pricing. Issues regarding gene therapy.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Monitored issues related to the medical supply chain. S. 4348, FDASLA Act of 2022 and H.R. 7667, Food and Drug Amendment of 2022, including issues related to PDUFA and accelerated approval pathways.
Agencies Lobbied
U.S. Senate
Lobbying Issues
H.R. 5376 (P.L. 117-169), the Inflation Reduction Act as it relates to the orphan drug credit, corporate and international taxes. Monitored H.R. 1304, the American Innovation and R&D Competitiveness Act; and S. 749, the American Innovation and Jobs Act; and issues related to the R&D tax credit.
Agencies Lobbied
U.S. Senate
Type of Issue
Taxation/Internal Revenue Code
Lobbying Issues
Monitored issues related to plasma donation.
Agencies Lobbied
White House Office
2nd Quarter, 2022
In Q2, THE NICKLES GROUP, LLC lobbied for CSL Behring LLC , earning $50,000. The report was filed on July 19, 2022.
Original Filing: 301387498.xml
Lobbying Issues
Issues related plasma therapies. Monitored issues related to value based payment arrangements. H.R. 5376, The Build Back Better Act, as it relates to plasma derived products and drug pricing.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Monitored issues related to the medical supply chain. Issues involving plasma donation. S. 4348, FDASLA Act of 2022 and H.R. 7667, Food and Drug Amendment of 2022, including issues related to PDUFA and accelerated approval pathways.
Agencies Lobbied
U.S. Senate
Lobbying Issues
H.R. 5376, the Build Back Better Act, as it relates to the orphan drug credit, corporate and international taxes.
Agencies Lobbied
U.S. Senate
Type of Issue
Taxation/Internal Revenue Code
Lobbying Issues
Issues related to plasma and plasma therapies. Issues involving promoting plasma donation. H.R. 5376, The Build Back Better Act, as it relates to drug pricing. S. 4348, FDASLA Act of 2022 and H.R. 7667, Food and Drug Amendment of 2022.
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
Issues related to plasma donation.
Agencies Lobbied
White House Office
1st Quarter, 2022
In Q1, THE NICKLES GROUP, LLC lobbied for CSL Behring LLC , earning $50,000. The report was filed on April 20, 2022.
Original Filing: 301369936.xml
Lobbying Issues
Issues related to home infusion and plasma therapies. Monitored issues related to value based payment arrangements. H.R. 5376, The Build Back Better Act, as it relates to plasma derived products and drug pricing.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Monitored issues related to the medical supply chain. Monitored issues related to FDA user fee agreements. Issues involving plasma donation.
Agencies Lobbied
U.S. Senate
Lobbying Issues
H.R. 5376, the Build Back Better Act, as it relates to the orphan drug credit, corporate and international taxes.
Agencies Lobbied
U.S. Senate
Type of Issue
Taxation/Internal Revenue Code
Lobbying Issues
Issues related to plasma and plasma therapies. Issues involving promoting plasma donation. H.R. 5376, The Build Back Better Act, as it relates to drug pricing.
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
Issues related to access to plasma and plasma therapies.
Agencies Lobbied
White House Office
4th Quarter, 2021
In Q4, THE NICKLES GROUP, LLC lobbied for CSL Behring LLC , earning $50,000. The report was filed on Jan. 18, 2022.
Original Filing: 301324942.xml
Lobbying Issues
Issues related to home infusion and plasma therapies. Monitored issues related to value based payment arrangements. Drug pricing issues related to H.R. 3, the Elijah E. Cummings Lower Drug Costs Now Act, H.R. 5376, The Build Back Better Act, and H.R. 19/S. 2164, the Lower Costs, More Cures Act. H.R. 5376, The Build Back Better Act, as it relates to plasma derived products and drug pricing.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Monitored issues related to the medical supply chain.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Monitored S.Con.Res. 14, FY 2022 Budget Resolution.
Agencies Lobbied
U.S. Senate
Lobbying Issues
H.R. 5376, the Build Back Better Act, as it relates to the orphan drug credit, corporate and international taxes.
Agencies Lobbied
U.S. Senate
Type of Issue
Taxation/Internal Revenue Code
Lobbying Issues
Issues related to plasma and plasma therapies. Monitored drug pricing issues related to H.R. 3, the Elijah E. Cummings Lower Drug Costs Now Act and H.R. 19, the Lower Costs, More Cures Act. H.R. 3684 (P.L. 117-58), The Infrastructure Investment and Jobs Act, as it relates to drug pricing. Issues involving promoting plasma donation. H.R. 5376, The Build Back Better Act, as it relates to drug pricing.
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
Issues related to access to plasma and plasma therapies.
Agencies Lobbied
White House Office
3rd Quarter, 2021
In Q3, THE NICKLES GROUP, LLC lobbied for CSL Behring LLC , earning $50,000. The report was filed on Oct. 20, 2021.
Original Filing: 301312784.xml
Lobbying Issues
Monitored issues related to home infusion and plasma therapies. Monitored issues related to value based payment arrangements. Drug pricing issues related to H.R. 3, the Elijah E. Cummings Lower Drug Costs Now Act, H.R. 5376, The Build Back Better Act, and H.R. 19/S. 2164, the Lower Costs, More Cures Act. H.R. 3684, The Infrastructure Investment and Jobs Act, as it relates to drug pricing.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Monitored issues related to drug pricing. Monitored issues related to the medical supply chain.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Monitored S.Con.Res. 14, FY 2022 Budget Resolution, as it relates to drug pricing and corporate taxes.
Agencies Lobbied
U.S. Senate
Lobbying Issues
H.R. 5376, the Build Back Better Act, as it relates to the orphan drug credit, corporate and international taxes.
Agencies Lobbied
U.S. Senate
Type of Issue
Taxation/Internal Revenue Code
Lobbying Issues
Issues related to plasma and plasma therapies. Monitored drug pricing issues related to H.R. 3, the Elijah E. Cummings Lower Drug Costs Now Act and H.R. 19, the Lower Costs, More Cures Act. H.R. 3684, The Infrastructure Investment and Jobs Act, as it relates to drug pricing. Issues involving promoting plasma donation. H.R. 5376, The Build Back Better Act, as it relates to drug pricing.
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
Issues related to access to plasma and plasma therapies.
Agencies Lobbied
White House Office
2nd Quarter, 2021
In Q2, THE NICKLES GROUP, LLC lobbied for CSL Behring LLC , earning $50,000. The report was filed on July 20, 2021.
Original Filing: 301284844.xml
Lobbying Issues
Monitored issues related to home infusion and plasma therapies. Monitored issues related to value based payment arrangements. Drug pricing issues related to H.R. 3, the Elijah E. Cummings Lower Drug Costs Now Act and H.R. 19/S. 2164, the Lower Costs, More Cures Act.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Issues involving promoting plasma donation. Monitored issues related to drug pricing. Monitored issues related to the medical supply chain. Issues related to access to plasma therapies.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Monitored FY 2022 Budget Resolution.
Agencies Lobbied
U.S. Senate
Lobbying Issues
American Jobs Plan, as it relates to corporate and international taxes.
Agencies Lobbied
U.S. Senate
Type of Issue
Taxation/Internal Revenue Code
Lobbying Issues
Issues related to plasma and plasma therapies. Monitored drug pricing issues related to H.R. 3, the Elijah E. Cummings Lower Drug Costs Now Act and H.R. 19, the Lower Costs, More Cures Act.
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
Monitored issues related to the medical supply chain and the Defense Production Act.
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
Issues related to access to plasma and plasma therapies.
Agencies Lobbied
White House Office
1st Quarter, 2021
In Q1, THE NICKLES GROUP, LLC lobbied for CSL Behring LLC , earning $50,000. The report was filed on April 16, 2021.
Original Filing: 301254096.xml
Lobbying Issues
Monitored issues related to home infusion and plasma therapies.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Issues involving promoting plasma donation and convalescent plasma donation. Monitored issues related to drug pricing. Monitored P.L. 117-2, the American Rescue Plan.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Monitored FY'21 Budget Resolution.
Agencies Lobbied
U.S. Senate
Lobbying Issues
American Jobs Plan, as it relates to corporate taxes.
Agencies Lobbied
U.S. Senate
Type of Issue
Taxation/Internal Revenue Code
4th Quarter, 2020
THE NICKLES GROUP, LLC amended a lobbying report for representation of CSL Behring LLC in Q42020 on Jan. 20, 2021.
Original Filing: 301239191.xml
Lobbying Issues
Issues related to home infusion and DME self-administered therapies. Issues regarding coverage and reimbursement of biologics and plasma therapies. Monitored issues related to H.R. 2905, Medicare IVIG Access Enhancement Act. Monitored S. 2543, Prescription Drug Pricing Reduction Act of 2019. S. 3457 / H.R. 6218, Preserving Patient Access to Home Infusion Act, as it relates to access to drugs listed on the self-administered drug list. H.R. 7839, Continuing Access to In-Home IVIG Act. H.R. 133, the Consolidated Appropriations Act of 2021, including home infusion and DME self-administered therapies. Issues concerning the most favored nation rule as it relates to plasma-derived products.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Issues involving promoting plasma donation and convalescent plasma donation; issues involving the development hyperimmune globulin treatment; monitored issues related to H.R. 925 / H.R. 8406, The HEROES Act and The Health, Economic Assistance, Liability Protection and Schools (HEALS) Act; H.R. 8337, Continuing Appropriations Act, 2021 and Other Extensions Act; S. 4317, SAFE TO WORK Act; S. 4322, Safely Back to School and Back to Work Act. H.R. 133, the Consolidated Appropriations Act of 2021. Monitored S.AMDT 2562 to S. 178, Delivering Immediate Relief to Americas Families, Schools and Small Businesses Act.
Agencies Lobbied
U.S. Senate
4th Quarter, 2020
In Q4, THE NICKLES GROUP, LLC lobbied for CSL Behring LLC , earning $50,000. The report was filed on Jan. 19, 2021.
Original Filing: 301234714.xml
Lobbying Issues
Issues related to home infusion and DME self-administered therapies. Issues regarding coverage and reimbursement of biologics and plasma therapies. Monitored issues related to H.R. 2905, Medicare IVIG Access Enhancement Act. Monitored S. 2543, Prescription Drug Pricing Reduction Act of 2019. S. 3457 / H.R. 6218, Preserving Patient Access to Home Infusion Act, as it relates to access to drugs listed on the self-administered drug list. H.R. 7839, Continuing Access to In-Home IVIG Act. H.R. 133, the Consolidated Appropriations Act of 2021, including home infusion and DME self-administered therapies. Issues concerning the most favored nation rule as it relates to plasma-derived products.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Issues involving promoting plasma donation and convalescent plasma donation; issues involving the development hyperimmune globulin treatment; monitored issues related to H.R. 925 / H.R. 8406, The HEROES Act and The Health, Economic Assistance, Liability Protection and Schools (HEALS) Act; H.R. 8337, Continuing Appropriations Act, 2021 and Other Extensions Act; S. 4317, SAFE TO WORK Act; S. 4322, Safely Back to School and Back to Work Act. H.R. 133, the Consolidated Appropriations Act of 2021. Monitored S.AMDT 2562 to S. 178, Delivering Immediate Relief to Americas Families, Schools and Small Businesses Act.
Agencies Lobbied
U.S. Senate
3rd Quarter, 2020
In Q3, THE NICKLES GROUP, LLC lobbied for CSL Behring LLC , earning $50,000. The report was filed on Oct. 19, 2020.
Original Filing: 301213788.xml
Lobbying Issues
Issues related to home infusion and DME self-administered therapies. Issues regarding coverage and reimbursement of biologics and plasma therapies. Monitored issues related to H.R. 2905, Medicare IVIG Access Enhancement Act. Monitored S. 2543, Prescription Drug Pricing Reduction Act of 2019. S. 3457 / H.R. 6218, Preserving Patient Access to Home Infusion Act, as it relates to access to drugs listed on the self-administered drug list. Issues related to the Executive Order on Lowering Drug Prices by Putting America First. H.R. 7839, Continuing Access to In-Home IVIG Act.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Issues involving promoting plasma donation and convalescent plasma donation; issues involving the development hyperimmune globulin treatment; monitored issues related to H.R. 925 / H.R. 8406, The HEROES Act and The Health, Economic Assistance, Liability Protection and Schools (HEALS) Act; H.R. 8337, Continuing Appropriations Act, 2021 and Other Extensions Act; S. 4317, SAFE TO WORK Act; S. 4322, Safely Back to School and Back to Work Act.
Agencies Lobbied
U.S. Senate
2nd Quarter, 2020
In Q2, THE NICKLES GROUP, LLC lobbied for CSL Behring LLC , earning $50,000. The report was filed on July 20, 2020.
Original Filing: 301198866.xml
Lobbying Issues
Issues related to home infusion and DME self-administered therapies. Issues regarding coverage and reimbursement of biologics and plasma therapies. Issues pertaining to drugs listed on the Self-Administered Drug list. Monitored issues related to H.R. 2905, Medicare IVIG Access Enhancement Act. Monitored S. 2543, Prescription Drug Pricing Reduction Act of 2019. S. 3457 / H.R. 6218, Preserving Patient Access to Home Infusion Act, as it relates to access to drugs listed on the self-administered drug list. Monitored issues related to drug pricing. Issues related to the corona virus.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Monitored issues related to prescription drug pricing. Monitored S. 1895, Lower Health Care Costs Act of 2019, as it relates to pricing transparency and drug pricing. Issues involving promoting plasma donation and convalescent plasma donation.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Monitored issues involving plasma donors from border countries.
Agencies Lobbied
Homeland Security - Dept of (DHS)
1st Quarter, 2020
In Q1, THE NICKLES GROUP, LLC lobbied for CSL Behring LLC , earning $50,000. The report was filed on April 20, 2020.
Original Filing: 301176760.xml
Lobbying Issues
Issues related to home infusion and DME self-administered therapies. Issues regarding coverage and reimbursement of biologics and plasma therapies. Issues pertaining to drugs listed on the Self-Administered Drug list. H.R. 2296, the METRIC Act. Monitored issues related to H.R. 2905, Medicare IVIG Access Enhancement Act. H.R. 2113, Prescription Drug STAR Act. Monitored S. 2543, Prescription Drug Pricing Reduction Act of 2019. H.R. 3, Elijah E. Cummings Lower Drug Costs Now Act. S. 3457 / H.R. 6218, Preserving Patient Access to Home Infusion Act, as it relates to access to drugs listed on the self-administered drug list. Monitored Coronavirus Aid, Relief and Economic Security "CARES Act," P.L. 116-136.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Monitored issues related to prescription drug pricing. H.R. 2296, the METRIC Act. Monitored S. 1895, Lower Health Care Costs Act of 2019, as it relates to pricing transparency and drug pricing. H.R. 2113, Prescription Drug STAR Act.
Agencies Lobbied
U.S. Senate
4th Quarter, 2019
In Q4, THE NICKLES GROUP, LLC lobbied for CSL Behring LLC , earning $50,000. The report was filed on Jan. 21, 2020.
Original Filing: 301127655.xml
Lobbying Issues
Issues related to home infusion and DME self-administered therapies. Issues regarding coverage reimbursement of biologics and plasma therapies. Issues pertaining to drugs listed on the Self-Administered Drug list. H.R. 2296, the METRIC Act. Monitored issues related to H.R. 2905, Medicare IVIG Access Enhancement Act. H.R. 2113, Prescription Drug STAR Act. Monitored S. 2543, Prescription Drug Pricing Reduction Act of 2019. H.R. 3, Elijah E. Cummings Lower Drug Costs Now Act.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Monitored issues related to prescription drug pricing. H.R. 2296, the METRIC Act. Monitored S. 1895, Lower Health Care Costs Act of 2019, as it relates to pricing transparency and drug pricing. H.R. 2113, Prescription Drug STAR Act.
Agencies Lobbied
U.S. Senate
Lobbying Issues
H.R. 1158, the Consolidated Appropriations Act of 2020; H.R. 1865, Further Consolidated Appropriations Act, 2020, as it relates to the self-administered drug list.
Agencies Lobbied
U.S. Senate
3rd Quarter, 2019
In Q3, THE NICKLES GROUP, LLC lobbied for CSL Behring LLC , earning $50,000. The report was filed on Oct. 17, 2019.
Original Filing: 301068784.xml
Lobbying Issues
Issues related to home infusion and DME self-administered therapies. Issues regarding coverage reimbursement of biologics and plasma therapies. Issues pertaining to drugs listed on the Self-Administered Drug list. H.R. 2296, the METRIC Act. Monitored issues related to H.R. 2905, Medicare IVIG Access Enhancement Act. H.R. 2113, Prescription Drug STAR Act. Monitored S. 2543, Prescription Drug Pricing Reduction Act of 2019.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Monitored issues related to prescription drug pricing. H.R. 2296, the METRIC Act. Monitored S. 1895, Lower Health Care Costs Act of 2019, as it relates to pricing transparency and drug pricing. H.R. 2113, Prescription Drug STAR Act.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Monitored H.R. 4378, the Continuing Appropriations Act of 2020 and Health Extenders Act of 2019.
Agencies Lobbied
U.S. Senate
2nd Quarter, 2019
In Q2, THE NICKLES GROUP, LLC lobbied for CSL Behring LLC , earning $50,000. The report was filed on July 22, 2019.
Original Filing: 301056995.xml
Lobbying Issues
Issues related to home infusion and DME self-administered therapies. Issues regarding reimbursement of drugs, biologics and plasma therapies. Issues pertaining to drugs listed on the Self-Administered Drug list. H.R. 2296, FAIR Drug Pricing Act of 2019. Monitored issues related to H.R. 2905, Medicare IVIG Access Enhancement Act. H.R. 2113, Prescription Drug STAR Act.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Issues related to orphan drug tax credit.
Type of Issue
Taxation/Internal Revenue Code
Lobbying Issues
Monitored issues related to prescription drug pricing. H.R. 2296, FAIR Drug Pricing Act of 2019. Monitored S. 1895, Lower Health Care Costs Act of 2019, as it relates to pricing transparency and drug pricing. H.R. 2113, Prescription Drug STAR Act.
Agencies Lobbied
U.S. Senate
1st Quarter, 2019
In Q1, THE NICKLES GROUP, LLC lobbied for CSL Behring LLC , earning $50,000. The report was filed on April 19, 2019.
Original Filing: 301031663.xml
Lobbying Issues
Issues related to home infusion and DME self-administered therapies. Issues regarding reimbursement of drugs, biologics and plasma therapies. Issues pertaining to drugs listed on the Self-Administered Drug list.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Issues related to orphan drug tax credit.
Type of Issue
Taxation/Internal Revenue Code
Lobbying Issues
Monitored issues related to prescription drug pricing.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Monitored issues related to the conference report accompanying H.J. Res 31.
Agencies Lobbied
U.S. Senate
1st Quarter, 2019
The Nickles Group, LLC filed a lobbying registration on Feb. 22, 2019 to represent CSL Behring LLC, effective Jan. 15, 2019.
Original Filing: 301020640.xml
Issue(s) they said they’d lobby about: Orphan Drug Act, Medicare payment for home infusion services, drug importation, drug pricing proposals included in Administration's Blueprint "America's Patients First" a plan to lower prescription drug prices. .
Source: Clerk of the U.S. House of Representatives and Secretary of the Senate
Searching...